La-Beck, N. M., Islam, M. R. & Markiewski, M. M. Nanoparticle-induced complement activation: implications for most cancers nanomedicine. Entrance. Immunol. 11, 603039 (2020).
Moghimi, S. M., Simberg, D., Papini, E. & Farhangrazi, Z. S. Complement activation by drug carriers and particulate prescribed drugs: rules, challenges and alternatives. Adv. Drug Deliv. Rev. 157, 83–95 (2020).
Ricklin, D., Hajishengallis, G., Yang, Okay. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785–797 (2010).
Szebeni, J., Simberg, D., Gonzalez-Fernandez, A., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and technique for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).
Moghimi, S. M. et al. Materials properties in complement activation. Adv. Drug Deliv. Rev. 63, 1000–1007 (2011).
Tavano, R. et al. C1q-mediated complement activation and C3 opsonization set off recognition of stealth poly(2-methyl-2-oxazoline)-coated cilica nanoparticles by human phagocytes. ACS Nano 12, 5834–5847 (2018).
Inturi, S. et al. Modulatory function of floor coating of superparamagnetic iron oxide nanoworms in complement opsonization and leukocyte pptake. ACS Nano 9, 10758–10768 (2015).
Dobrovolskaia, M. A., Aggarwal, P., Corridor, J. B. & McNeil, S. E. Preclinical research to know nanoparticle interplay with the immune system and its potential results on nanoparticle biodistribution. Mol. Pharm. 5, 487–495 (2008).
Ricklin, D. & Lambris, J. D. Complement in immune and inflammatory problems: pathophysiological mechanisms. J. Immunol. 190, 3831–3838 (2013).
Moghimi, S. M. Most cancers nanomedicine and the complement system activation paradigm: anaphylaxis and tumour progress. J. Management. Launch 190, 556–562 (2014).
Forneris, F. et al. Regulators of complement exercise mediate inhibitory mechanisms by way of a typical C3b-binding mode. EMBO J. 35, 1133–1149 (2016).
Schmidt, C. Q., Lambris, J. D. & Ricklin, D. Safety of host cells by complement regulators. Immunol. Rev. 274, 152–171 (2016).
Zipfel, P. F. & Skerka, C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729–740 (2009).
Morgan, B. P. & Harris, C. L. Complement, a goal for remedy in inflammatory and degenerative illnesses. Nat. Rev. Drug Discov. 14, 857–877 (2015).
Mastellos, D. C., Ricklin, D. & Lambris, J. D. Scientific promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 18, 707–729 (2019).
Smith, G. P. & Smith, R. A. Membrane-targeted complement inhibitors. Mol. Immunol. 38, 249–255 (2001).
Gaikwad, H. et al. Complement inhibitors block complement C3 opsonization and enhance focusing on selectivity of nanoparticles in blood. Bioconjugate Chem. 31, 1844–1856 (2020).
Gifford, G. et al. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J. Management. Launch 302, 181–189 (2019).
Belling, J. N. et al. Stealth immune properties of graphene oxide enabled by surface-bound complement issue H. ACS Nano 10, 10161–10172 (2016).
Wang, Z. et al. Combating complement’s deleterious results on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv. Mater. 34, e2107070 (2022).
Souza, D. G., Esser, D., Bradford, R., Vieira, A. T. & Teixeira, M. M. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that comply with intestinal ischaemia and reperfusion harm. Br. J. Pharmacol. 145, 1027–1034 (2005).
White, J. et al. Organic exercise, membrane-targeting modification, and crystallization of soluble human decay accelerating issue expressed in E. coli. Protein Sci. 13, 2406–2415 (2004).
Bechtler, C. et al. Complement-regulatory biomaterial coatings: exercise and selectivity profile of the issue H-binding peptide 5C6. Acta Biomater. 155, 123–138 (2023).
Hare, J. I. et al. Challenges and techniques in anti-cancer nanomedicine growth: an business perspective. Adv. Drug Deliv. Rev. 108, 25–38 (2017).
Benamu, E. & Montoya, J. G. Infections related to the usage of eculizumab: suggestions for prevention and prophylaxis. Curr. Opin. Infect. Dis. 29, 319–329 (2016).
Barnum, S. R. Therapeutic inhibition of complement: nicely definitely worth the threat. Pattern Pharmacol. Sci. 38, 503–505 (2017).
van den Elsen, J. M. & Isenman, D. E. A crystal construction of the advanced between human complement receptor 2 and its ligand C3d. Science 332, 608–611 (2011).
Farries, T. C., Seya, T., Harrison, R. A. & Atkinson, J. P. Competitors for binding websites on C3b by CR1, CR2, MCP, issue B and issue H. Complement Inflamm. 7, 30–41 (1990).
Holers, M. et al. The human complement receptor kind 2 (CR2)/CR1 fusion protein TT32, a focused inhibitor of the classical and different pathway C3 convertases, prevents arthritis in lively immunization and passive switch fashions and acts by CR2-dependent focusing on of CR1 regulatory exercise. Immunobiology 217, 1210–1210 (2012).
Holers, V. M., Rohrer, B. & Tomlinson, S. CR2-mediated focusing on of complement inhibitors: bench-to-bedside utilizing a novel technique for site-specific complement modulation. Adv. Exp. Med. Biol. 735, 137–154 (2013).
Huang, Y. X., Qiao, F., Atkinson, C., Holers, V. M. & Tomlinson, S. A novel focused inhibitor of the choice pathway of complement and its therapeutic software in ischemia/reperfusion harm. J. Immunol. 181, 8068–8076 (2008).
Risitano, A. M. et al. The complement receptor 2/issue H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119, 6307–6316 (2012).
Tomlinson, S. & Thurman, J. M. Tissue-targeted complement therapeutics. Mol. Immunol. 102, 120–128 (2018).
Risitano, A. M. et al. Security and pharmacokinetics of the complement inhibitor TT30 in a section I trial for untreated PNH sufferers. Blood 126, 2137 (2015).
Fridkis-Hareli, M. et al. The human complement receptor kind 2 (CR2)/CR1 fusion protein TT32, a novel focused inhibitor of the classical and different pathway C3 convertases, prevents arthritis in lively immunization and passive switch mouse fashions. Mol. Immunol. 105, 150–164 (2019).
Music, H., Qiao, F., Atkinson, C., Holers, V. M. & Tomlinson, S. A complement C3 inhibitor particularly focused to websites of complement activation successfully ameliorates collagen-induced arthritis in DBA/1J mice. J. Immunol. 179, 7860–7867 (2007).
Kim, Y. U. et al. Mouse complement regulatory protein Crry/p65 makes use of the precise mechanisms of each human decay-accelerating issue and membrane cofactor protein. J. Exp. Med. 181, 151–159 (1995).
Benasutti, H. et al. Variability of complement response towards preclinical and scientific nanocarriers within the common inhabitants. Bioconjugate Chem. 28, 2747–2755 (2017).
Berger, N. et al. New analogs of the complement C3 inhibitor compstatin with elevated solubility and improved pharmacokinetic profile. J. Med. Chem. 61, 6153–6162 (2018).
Lamers, C. et al. Perception into mode-of-action and structural determinants of the compstatin household of scientific complement inhibitors. Nat. Commun. 13, 5519 (2022).
Guthridge, J. M. et al. Epitope mapping utilizing the X-ray crystallographic construction of complement receptor kind 2 (CR2)/CD21: identification of a extremely inhibitory monoclonal antibody that instantly acknowledges the CR2-C3d interface. J. Immunol. 167, 5758–5766 (2001).
Chen, F. et al. Complement proteins bind to nanoparticle protein corona and endure dynamic change in vivo. Nat. Nanotechnol. 12, 387–393 (2017).
Venkatesh, Y. P., Minich, T. M., Legislation, S. Okay. & Levine, R. P. Pure launch of covalently sure C3b from cell surfaces and the examine of this phenomenon within the fluid-phase system. J. Immunol. 132, 1435–1439 (1984).
Li, Y. et al. Complement opsonization of nanoparticles: variations between people and preclinical species. J. Management. Launch 338, 548–556 (2021).
Hardy, M. P., Rowe, T. & Wymann, S. Soluble complement receptor 1 therapeutics. J. Immunol. Sci. 6, 1–17 (2022).
Voorhees, A. B., Baker, H. J. & Pulaski, E. J. Reactions of albino rats to injections of dextran. Proc. Soc. Exp. Biol. Med. 76, 254–256 (1951).
Dezsi, L. et al. Complement activation-related pathophysiological adjustments in anesthetized rats: activator-dependent variations of signs and mediators of pseudoallergy. Molecules 24, 3283 (2019).
Timotius, I. Okay. et al. Mixture of outlined catwalk gait parameters for predictive locomotion restoration in experimental spinal wire harm rat fashions. eNeuro 8, 0497-20.2021 (2021).
Chen, E. et al. Untimely drug launch from polyethylene glycol (PEG)-coated liposomal doxorubicin through formation of the membrane assault advanced. ACS Nano 14, 7808–7822 (2020).
Munter, R. et al. Unravelling heterogeneities in complement and antibody opsonization of particular person liposomes as a operate of floor structure. Small 18, e2106529 (2022).
Vu, V. P. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization effectivity of preclinical and scientific nanoparticles. Nat. Nanotechnol. 14, 260–268 (2019).
Wang, G. et al. In vitro and in vivo variations in murine third complement element (C3) opsonization and macrophage/leukocyte responses to antibody-functionalized iron oxide nanoworms. Entrance. Immunol. 8, 151 (2017).
Wang, G. et al. Activation of human complement system by dextran-coated iron oxide nanoparticles shouldn’t be affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking. Entrance. Immunol. 7, 418 (2016).
Moghimi, S. M. & Simberg, D. Crucial points and pitfalls in serum and plasma dealing with for complement evaluation in nanomedicine and bionanotechnology. Nano At the moment 44, 101479 (2022).
Wu, L.-P. et al. Dendrimer end-terminal motif-dependent evasion of human complement and complement activation by way of IgM hitchhiking. Nat. Commun. 12, 4858 (2021).
Wang, G. et al. Excessive-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. ACS Nano 8, 12437–12449 (2014).
